Antibiotic prophylaxis in acute childhood leukemia: What is known so far?
Hematol., Transfus. Cell Ther. (Impr.)
; 45(4): 473-482, Oct.-Dec. 2023. tab
Article
in English
| LILACS
| ID: biblio-1528645
Responsible library:
BR408.1
Localization: BR408.1
ABSTRACT
ABSTRACT Introduction:
The treatment of acute lymphoblastic leukemia (ALL) has evolved in recent decades, reaching an overall survival rate close to 90%. Currently, approximately 4% of patients with ALL die from secondary complications of chemotherapy. Among these complications, the most frequent is febrile neutropenia (FN). The treatment of acute myeloid leukemias (AMLs) is even more aggressive, being consequently related to a considerable amount of treatment-related toxicity with a high risk of severe infection and death.Method:
In order to reduce the infection-related risks in these groups of patients, systemic antibacterial prophylaxis has emerged as a possible approach.Results:
Antibiotic prophylaxis during neutropenia periods in those undergoing chemotherapy have .already been proven in adults with acute leukemias (ALs). Among the possible available therapeutic options for bacterial prophylaxis in children with cancer, fluoroquinolones emerged with the most amount of evidence. Within this class, levofloxacin became the best choice.Conclusion:
Therefore, the use of levofloxacin seems to be indicated in very specific situations in children who are known to be neutropenic for a long time, secondary to intensive chemotherapy; in children with AL undergoing chemotherapy to induce remission; or in children undergoing hematopoietic stem cell transplantation (HSCT). This article aims to describe recent evidence focusing on antibiotic prophylaxis in children with ALs.
Full text:
Available
Collection:
International databases
Health context:
SDG3 - Health and Well-Being
/
SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases
/
SDG3 - Target 3.2 Reduce avoidable death in newborns and children under 5
Health problem:
Target 3.2: Reduce avoidable death in newborns and children under 5
/
Leukemia
/
Infections
/
Noncommunicable Diseases
Database:
LILACS
Main subject:
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Language:
English
Journal:
Hematol., Transfus. Cell Ther. (Impr.)
Journal subject:
Hematologia
/
TransfusÆo de Sangue
Year:
2023
Document type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Instituto de Oncologia Pediátrica - GRAACC/BR
/
Santa Casa de Misericórdia de Porto Alegre/BR
/
Universidade Federal do Rio Grande do Sul (UFRGS)/BR